Myasthenia gravis is a disorder of impaired neuromuscular transmission resulting in
weakness and abnormal fatigability on exertion, improved by anti-acetyl cholinesterase …

Myasthenia gravis is a neuromuscular junction disorder characterised by fluctuating muscle
weakness, improved by using anti-cholinesterase drugs. In addition to the autoimmune …

Wilson's disease (WD) is a genetic disorder with copper accumulation in various tissues
leading to related clinical symptoms (mainly hepatic and neuropsychiatric) which can be in …

The temporal course and pathophysiology of penicillamine‐induced myasthenia gravis were
studied in detail in a typical case. Our results suggest that this disorder and idiopathic …

D-penicillamine has been used in the treatment of rheumatoid arthritis for years. As a rare
complication of this treatment the occurrence of myasthenia gravis has been described, the …

We have encountered a 53 year-old female with myasthenia gravis (MG) possibly induced
by the treatment with D-penicillamine (D-pc). She has had a long-standing history of …

Electroneuromyographic studies have been reported as abnormal in only 9 of 23 cases of
penicillamine-associated myasthenia gravis (MG). We report a patient with rheumatoid …

In the D-penicillamine induced myasthenia gravis, ptosis and diplopia may occur usually six
to seven months after starting therapy. Muscular weakness is usually improved two to three …

The authors report a case of myasthenia gravis syndrome appearing six months after the
start of d-Penicillamine treatment for rheumatoid polyarthritis and disappearing rapidly and …

ABSTRACT D-penicillamine, a drug used to treat rheumatoid arthritis, Wilson's disease, and
cystinuria, can cause myasthenia gravis. Fortunately, the myasthenia typically resolves after …